Authors: J. Ribeiro 1;  R. P. Pirraco 2;  R. Horta 1,3
Authors‘ workplace: Faculdade de Medicina da Universidade do Porto, Porto, Portugal 1;  3B’s Research Group – Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European, Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal 2;  Department of Plastic, Reconstructive and Maxillo-Facial Surgery, and Burn Unity, Centro Hospitalar de São João, Porto, Medical School, Porto, Portugal 3
Published in: ACTA CHIRURGIAE PLASTICAE, 62, 3-4, 2020, pp. 103-110


Tissue engineering (TE) was firstly defined as “the application of the principles and methods of engineering and the life sciences towards the fundamental understanding of structure–function relationships in normal and pathologic mammalian tissues and the development of biologic substitutes that restore, maintain, or improve tissue function” 1,2. This relies on interdisciplinary collaboration between cell biologists, material engineers, biotechnologists, various medical specialties and industry manufacturers3.

TE and Plastic surgery share the common goal of restoring structure and function4. TE has the potential to reduce morbidity of the current approaches by eradicating donor site lesions, reducing hospital stay and the associated risks and costs3. Classic TE approaches encompass three components for regeneration: cells to form a matrix, a scaffold for transplantation and temporary support, and environmental factors2,3,5–8.

Possible cell sources include embryonic stem cells, adult stem cells and differentiated cells3,5,6,8,9. Embryonic stem cells are totipotent; however, they are difficult to obtain and raise ethical objections and concerns of tumorigenicity3. Mesenchymal stem cells (MSC) can be pluripotent or multipotent, they can be tissue derived, are available in large quantities and are increasingly recognized as the preferable cell source3,8. Induced pluripotent stem cells discovered by Takahashi and Yamanaka10 made possible the use of somatic cells in tissue engineering by reversing their differentiation state into pluripotent cells, but their use is still at its infancy3,8,9.

Scaffolds are designed to guide and support cells, allowing a physiologic three-dimensional proliferation and differentiation5–9. They can be biological or synthetic, depending on the fabrication materials. Furthermore, they can be solid, which requires surgical implantation, or can exhibit gel form, which – when injected – acquire the appropriated form of the defect in situ3,6.

Environmental factors consist of bioactive molecules (growth factors and cytokines), oxygen tension and mechanical or electrical stimulation, that alter cell’s response, improving wound healing and regeneration3,5,7,9,11.

This review will present an overview of published literature regarding tissue engineering in plastic surgery in clinical and pre-clinical studies, its current cells’ sources and applications, its disadvantages and future perspectives.

The aim of this work is to create awareness regarding one of the medicine’s greatest evolutions and the importance of implementation into practice of these new methods in reconstructive and aesthetic plastic surgery.


Tissue engineering is the promising alternative to the current plastic and reconstructive surgery approaches and has yielded small successes so far.

Below, a brief outline of the various current and potential therapeutic applications of tissue engineering, the multiple tissue sources and their uses (Figure 1), are presented.


The traditional autologous and allogeneic epidermal sheets have been proven successful in wound repair. However, they are limited in treating extensive wounds and fail to prevent wound contraction12.

There are multiple bioengineered products used in skin defects (Table 1). These derivatives, besides their indications, vary in administration, preservation, shelf life (acellular derivatives have longer shelf life, lasting years) and host immune response (present with porcine or bovine derivatives)9,13,14.

Topical therapies have the ability to promote wound vascularization promotion, reduce wound contraction and induce keratinization9,15. For example, recombinant human granulocyte/macrophage colony-stimulating factor (GM-CSF) topically applied had positive effects on venous and diabetic ulcers of the lower limb16. Also, Regranex, recombinant human PDGF, decreases wound closure time and increases complete wound healing9; this topical gel is used on diabetic neuropathic ulcers and advanced stage pressure ulcers, with great results, but as a growth factor, its application caries risk of malignancy9,16.

Adipose tissue is a popular source of stem cells for wound healing15–19. The paracrine effect of adipose-derived stem cells (ADSC) stimulates the secretion of cytokines with anti-inflammatory properties and induces skin neovascularization. Furthermore, they recruit endogenous stem cells and have secretory effects over dermal fibroblasts and keratinocytes15,19. ADSC suspension in saline and platelet rich plasma (PRP) injected showed to be particularly successful in cases with small areas of skin necrosis after hyaluronic acid filler injection18,20. In Korea, this is widely used over hyaluronidase, and is very effective in the relief of local ischemia and pain18,20.

Autologous ADSC administered by repeated hypoinvasive computer-assisted injections showed systematic improvement or remission in all 20 patients treated for chronic ulcers caused by radiotherapy17.

Immersion of scaffolds in an ADSC cell suspension has been used for the treatment of recurrent or chronic cutane­ous lesions, such as diabetic or chronic radiation ulcers18. As an example, Terudermis is used as an artificial dermis that must be sutured to adjacent skin as a protective sur­face. This approach may be an option for small traumatic defects or skin cancers to avoid the use of local flaps18.

Cell sheet engineering, is a promising alternative that consists in a scaffold-free tissue-engineered product obtained through the culture of ADSC or human keratinocytes, dermal fibroblasts and dermal microvascular endothelial cells on a thermoresponsive surface or a standard cell culture surface12,15. Studies conducted on mice showed a short culture time period, great stability, high cell survival, high cell residence time and a stable neovascularization, which impacts on full-thickness skin regeneration12,15.

The use of ADSC combined with Platelet-rich plasma (PRP) potentiate adipogenesis and graft maintenance, especially in association with insulin19. PRP is a small volume of plasma concentrated with autologous human platelets and growth factors, it is currently used in regenerative medicine due to its capacity to stimulate tissue regeneration16,17,21.

PRP is indicated in a mixture with fat for chronic or post-traumatic ulcers and loss of substance of the lower limbs16,17,21. PRP used independently in a gel form or as an injection demonstrated great results in chronic/non-healing cutaneous ulcers, acute limb soft tissue wounds, trauma wounds and to stop bleeding in surgical flaps16,21,22. Possible associated risks include recurrence and growth of a pre-existing tumour16.

As mentioned above, keratinocytes and fibroblasts are used in several tissue-engineered constructs. These constructs have several indications as aforementioned, but it is still unclear when they should be indicated over a skin graft9.

Deformities associated with burn injury are frequently treated by plastic surgery procedures. Their incidence is increasing and they can lead to deadly consequences like burn shock and sepsis23,24. Currently, burn wounds’ treatment is based on the removal of devitalized tissue and coverage with an autologous split-thickness skin graft, but if the burned surface area is large this technique loses its value23. Temporary skin substitutes consist of biologically active patches that provide protection from infection and trauma, and provide pain control, while re-epithelialization occurs23. For example, Integra Dermal Regeneration Template is commonly used as a temporary approach in burn reconstruction, consisting of a layer of collagen and glycosaminoglycan covered by a semipermeable silicone9. Nowadays, as mentioned, there are already several bioengineered permanent skin substitutes in burn healing, including the FDA approved substitute, for treatment of severely burned patients – Epicel 9,13. Apligraf and Dermagraft need to undergo more clinical trials to evaluate their potential in burn injuries7,13.

Scarring is incomplete healing that leaves some deformation and/or defect18. Scars can affect negatively the appearance, can engender psychological illness, low self-esteem and isolation. ADSC therapy can be used to modulate scar formation. These cells injected repeatedly into the scarred tissue bed cause the scar to become soft, altering its remodelling process, which may avoid secondary surgery18. Although there is no scientific data published, ADSC-based cell therapy is used for prevention of scaring in severe facial trauma18. In clinical settings, if the healing process of an extensive wound will predictively take more than 2 weeks, skin grafting is advisable to minimize scarring25. There are two skin substitutes constructs indicated for scar reconstruction: SureDerm (acellular human cadaveric dermis) and Integra, used in burn scar contractures and keloid scars reconstructions25.

Researchers believe that, by solving how to rapidly revascularize grafts/substitutes, the acceleration of the wound healing process will limit scar formation25. The goal for TE is therefore the generation of prevascularized constructs able to be transplantable with standard microsurgical anastomotic techniques. Klar et al. 26, for the first time, used adipose tissue’s stromal vascular fraction (SVF) for assembling a capillary plexus, for anastomosis with the recipient’s circulation, and transplanted it onto immune-deficient rats. This was beneficial in achieving an increased graft dimension and absence of shrinkage26.

In the lab: At the 3B’s Research Group, alternative methodologies for wound healing are being explored. Innovative scaffolds such as spongy-like hydrogels were shown to improve healing outcomes in animal27–30, also by promoting neovascularization. The same was verified using cell sheet engineering, a scaffold-free strategy that uses sheets of cells, being a completely biologic approach (Figure 2)12,15.


Adipose derived stem cells have similar differentiation potential as bone marrow-derived MSC. They are easily harvested from lipoaspirates through enzymatic dissociation (with e.g. collagenase) and isolation from the SVF4,7,8,13,31. ADSC can then be used as a cell suspension, mixed with aspirated fat or seeded onto scaffolds8. Minonzio et al.31 demonstrates that these cells can be preserved frozen without losing their ability to differentiate. This justifies the existence of a new business of ADSC banking18.

Fat grafting is a frequent procedure used for soft tissue filling, but it has the disadvantage of significant absorption (40% to 80%) of the transplanted fat8,13,32. Contour deformities can cause both aesthetic and functional problems32. Many permanent (e.g. silicone, polymethyl-methacrylate) and temporary (e.g. HA, collagen) fillers are used, however, they often have poor results and complications33. ADSC in combination with fat grafting are indicated for volume restoration, because of their capacity to increase fat tissue survival rates, promote higher connective tissue formation, decrease necrotic tissue and improve patient satisfaction32,34. Bashir et al.32 was the first to report clinically the use of ex vivo expanded ADSC-enriched fat graft for facial lipodystrophy13,35,36. This combination use was also reported in lower limb atrophy from critical limb ischemia13,35 and chronic ulcers caused by radiation therapy16,17.

Fat grafts enriched with ADSC were also used for breast augmentation, with cosmetic or cancer reconstruction purposes8,13,17,36–38. Their application resulted in breast’s circumference enlargement, with minimal absorption and reduced complications39,40. However, these cells secrete proangiogenic growth factors, that may result in an increased breast cancer’s metastatic risk37. ADSC were found to increase growth of active tumour cells but not resting tumour cells41, while other study demonstrated that the risk depended on the delivery methods42. In contrast, there are also reports of a decrease in tumour growth and metastasis index37,43.

Inoculation of Crohn’s disease fistulas external openings with autologous ADSC was successful in 6 of 20 patients in a pilot study16,17. Since then, this technique was used to repair tracheomediastinal fistulas caused by cancer ablation16,17,44.

ADSC, due to their immunomodulatory and anti-inflammatory effects, were used in other autoimmune diseases such as systemic lupus erythematosus, autoimmune arthritis, rheumatoid arthritis and acute graft-versus-host disease16. They also have applications for neural regeneration in Parkinson’s and Alzheimer’s disease16,19; hepatic regeneration16; and mixed with PRP for age-related macular degeneration and corneal epithelium repair13,16,17,19.


Head and neck structures control several senses, vital functions, the swallowing process, communication, facial animation and aesthetics45. Craniofacial defects can be congenital (e.g. cleft lip, calvarial defects or Romberg syndrome) or acquired (e.g. trauma or oncological resection)45–47. The functional, aesthetic and social effects resulting from these anomalies can severally affect the patient’s quality-of-life45,46.

Soft tissue defects causing facial contour deformities require soft tissue augmentation therapies that usually consist of autologous fat grafting32. Case reports and prospective studies showed that ADSC enriched fat is more beneficial for facial contour deformities repair, reducing the need to repeat the grafting32,34. This combination is indicated for loss of substance on the face, volume loss in aging, hemifacial microsomia, scleroderma, Parry-Romberg syndrome and in facial skin necrosis16–18. PRP therapies have shown benefits in deep-plane rhytidectomy (for reducing tissue inflammation, oedema and ecchymosis)48–50, Romberg syndrome and facial tissue atrophy type 1 and 2 51–54.

Cranial bone defects are extremely common in children55. In craniofacial bone’s replacement higher porosity is essential for vascularization, osteoblast proliferation and migration, but this leads to lower mechanical properties46. For bone replacement, it is thought to be essential to incorporate mineral phases onto the scaffolds for osteoinductivity46,56. Calvarial defects are usually treated with cranioplasty using autologous bone grafting, titanium mesh implants or polymethylmethacrylate45. Several animal and human studies showed promising results with the use of ADSC in tissue engineered constructs for these defects9,13,16,17,45,57. Case reports demonstrate new bone formation using ADSC in combination with an autologous cancellous bone from the iliac crest and fibrin glue for calvarial traumatic defects, without using exogenous growth factors57,58. The benefits of ADSC use were also reported in mandibular, maxilla, frontal sinus and nasal septum defects59.

Bone marrow-derived MSC were beneficial on the improvement of bone defects healing60 and have been used for a functional neomandible creation61.

There is also a FDA approved product for alveolar ridge augmentation, including in alveolar clefts, INFUSE bone graft, that consists of a collagen sponge soaked with recombinant human BMP-262.

Cartilage tissue engineering could provide adequate amounts of tissue to overcome the cartilage donor site shortage and morbidity45,47. Nasal lesions often occur after oncologic resection of skin cancers, this resection is usually very mutilating requiring multiple local skin flaps47. Injected gelatinous chondroid matrix with chondrocytes harvested from the auricular cartilage, was used for nasal augmentation, with formation of hard neocartilage and satisfactory long-lasting effects63. In other human trial, resected alar cartilage was replaced with a tissue engineered mesh; however, the authors were incapable of proving the cartilaginous and not scar nature of the neotissue64.

One of the biggest challenges in plastic surgery is auricle reconstruction, due to acquired or congenital deformities (e.g. microtia and prominent ears) 4,65. The current treatments for these defects include an auricular shaped autologous rib cartilage or artificial implants4,45,47,65. One human trial, including 4 patients with microtia, showed, with great results, the possibility of injecting cultured chondrocytes into the subcutaneous pocket on the fascia of the lower abdomen to form a neocartilage block that was surgically harvested and carved into the shape of the auricle and implanted66. TE in nasal and auricle reconstruction is far advanced in animal studies, but still lacks human trials; there are high hopes for cartilage culture methods of chondrocytes or pluripotent stem cells on 3D scaffolds4,45,47,65.

Tracheal defects can be life-threatening. The current synthetic materials that have been used as tracheal substitutes present a risk of granulation formation or stenosis, and allografts imply the need for lifelong immunosuppression47. There are several tissue- engineered substitutes, such as decellularized tracheal allografts9,47,67,68, a rigid prosthetic tube lined by a free radial forearm flap9,68,69, a decellularized tracheal autograft with bone marrow MSC and bronchial stem cells11,70, and a tracheal allograft combined with a buccal mucosal graft9,68,71. A case report of the use of a decellularized tracheal autograft repopulated with recipient’s respiratory epithelium and mesenchymal stromal cells on a 10-year-old child showed that the graft was completely integrated, but there was no proof of neocartilage formation and it didn’t grow like the adjacent native trachea47,70.

The laryngeal structures require a complex neural control and integration into reflex movement patterns. Therefore, tissue engineered laryngeal substitutes are still in a preclinical stage, since vocal fold motion has not yet been achieved47.


The actual gold standards for bone defects are autologous bone grafting and cadaveric/decellularized bone allografts5,9. These methods are limited by variable graft resorption72,73, risk of graft infection72 and the potential of disease transmission9,73.

Bone TE has been applied for years, in simpler forms such as corticotomy for osteoinduction9. Nowadays, the tissue engineered methods include transplantation of in vitro cultivated cells and guided tissue regeneration with bone mass or artificial material4. Osteoblasts, MSC, embryonic and skeletal muscle stem cells, all present osteogenic potential8. Scaffolds with calcium phosphate, hydroxyapatite, silica and collagen as the matrix are seen as necessary8.

The first reported tissue engineered bone repair was in 2001. Bone marrow MSC were used in 3 patients to treat large bone defects, from the tibia, ulna and humerus74. The INFUSE bone graft, used for alveolar clefts repair, can also be used for open tibial shaft fractures62. A similar product, OP-1 Implant, consisting of recombinant human BMP-2 with a bovine collagen carrier, was FDA approved for long bones non-union refractory lesions9,75. MSC transplantations improved hematopoietic stem cell engraftment for healing critical sized bone defects and for children with osteogenesis imperfecta11,61.

The current treatments for articular cartilage injury are essentially for symptoms’ control19. Bone marrow MSC, cultured in a collagen gel scaffold, are useful in TE for intervertebral disk replacement, knee joint resurfacing and digital-joint engineering5,11,76,77. These cells were also used to repair articular defects with intra-articular injections78. These treatments showed efficiency in reducing pain and improving walking ability13. Other treatment alternative is expanded autologous chondrocytes re-injected into the defect79. With engineered cartilage, it is difficult to obtain a secure healing of the cartilage to the underlying bone7 and there is a danger of dedifferentiation of cells in chondrogenic grafts into fibroblastoid cells5.

Tendon and muscle repair with tissue engineering techniques is still at a pre-clinical phase, with promising results in animal trials8,19. Bone marrow MSC and ADSC were described in several studies as useful in increasing tendon repair and tensile strength19. Recently was identified Growth Differentiation Factor – 5 as possibly having a significant role in tenogenic differentiation, but further studies are needed80.

Engineering of skeletal muscle is challenging due to its complex microelectrical and mechanical networks8. Mechanical stimulation, electrical stimulation and vascularization of constructs, with myoblasts or myogenic stem cells in vitro, showed great potential for future approaches8,81.


The current replacement options for peripheral nerve defects include autologous, allogeneic and acellular nerve grafts, that are limited by neuroma formation, immune reaction and delayed regeneration, respectively8,82. Schwann cell transplantation showed capacity to enhance peripheral nerve repair and are considered the most suitable cell type for neural regeneration. However, there is considerable donor-site morbidity, these cells have a slow proliferation rate and cell transplantation alone is limited by suboptimal spatial arrangement4,8,19. Bone marrow MSC and ADSC have also shown success in enhancing neural regeneration by releasing neurotrophic factors, in vitro and in animal models8,19,83,84.


When vascular grafts are needed in reconstructive surgery, the actual options are autologous vessels, which can be useless due to a disease, or synthetic grafts, which are prothrombotic8. The first bioengineered vessel was clinically used in 1999, on a four-year-old girl, to repair a total occlusion of the right intermediate pulmonary artery85. The construct was created by seeding cells extracted from the wall of a peripheral vessel into a biodegradable tube85. L’Heureux et al.86 created a vessel with cultured human vascular smooth muscle cells without any synthetic material. The vessel displayed similar strength to a human vessel and demonstrated to be functional in vivo in animal models. A clinical trial examined the use of these vessel grafts as arteriovenous shunt in end-stage renal disease patients87. Expanded findings from this study showed that the majority of the patients enrolled had successful implantations87.

Niklason et al. 88 reported a production of arbitrary lengths of bovine vascular conducts from smooth muscle and endothelial cells culture under pulsatile stimuli in vitro; these constructs demonstrated contractile responses including responses to pharmacological agents.

Smooth muscle cells (SMC) have limited proliferation and cultural senescence89. One study attempted to derive SMC from human hair follicle stem cells culture. These expressed similar markers to the SMC from human umbilical artery and also showed contractile function89. This could be a future reliable source of SMC for blood vessel engineering.

MSCs were also used in vascularization strategies, showing their potential to differentiate into endothelial cells, to promote endothelial repair by secretion of paracrine factors and prevent neointimal formation19.

Clinical testing on human bone marrow MSCs, ADSCs, fetal stem cells, hematopoietic stem cells and others, showed their vascularization benefits in myocardial post-ischemic neovascularization, neovascularization in systemic sclerosis, myogenic regeneration and neovascularization in erectile dysfunction, angiogenesis in nonrevascularizable limb ischemia, wound neovascularization and cerebral injury revascularization16.

The cell sheet technique was used as a vascularization strategy, without the use of extrinsic growth factors, with capillary-like structures organization when under hypoxic conditions90.

In the lab: To tackle the current limitations related with the vascularization of constructs, the 3B’s Research Group proposed the use of the Stromal Vascular Fraction of Adipose Tissue as a vascularization tool91. Cell sheets of SVF were shown to restore blood flux in a hind-limb ischemia mouse model90. SVF can also be used in combination with scaffolds, allowing their pre-vascularization without the use of growth factors (Figure 3).


The potential for tissue engineering is very big, however there are problems still to solve. There is the challenge of meeting the scientific needs while creating a durable and functional tissue and, at the same time, facing the complex regulatory processes until approval for human use3. Researchers need to better understand the role, interactions and fate of stem cells. Large constructs will still be limited by poor blood supply until significantly improved tissue engineering vascularization strategies arise. And the possible side effects (including malignancies) of growth factors recurrent use in tissue engineering is still unknown3,8,16. Besides these biological problems, there is an increase in health care costs, regulatory restrictions and ethical concerns, that contribute to the delay of tissue engineering widespread application8.

To allow this integration of tissue engineered constructs into clinical practice, there is the need for a multidisciplinary team, a clear understanding of manufacturing workflow and to understand the possibility/need of storage into specialized banks3,8,23.

Tissue engineering has the potential to revolutionize clinical practice as we know it. Small successes so far were achieved, especially in plastic and reconstructive surgery, but there is still a great need for further investigations and clinical trials before this becomes reality.

Statement: There are no conflict of interest in relation with the theme, creating and publication of this manuscript. There was no financial support during the preparation of the article.

Declaration (Ethical Standards): All procedures performed in this study involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards.

Funding: The authors have no financial disclosures to declare.

Conflicts of interest: The authors have no conflicts of interest.

Author(s) Contribution: All the authors have made a significant contribution to this manuscript, have seen and approved the final manuscript, and have agreed to its submission. 

Address for correspondence:

Juliana Ribeiro, MD

Avenida de São Mamede nº 535, 4560-800 Penafiel, Portugal

E-mail: juliana.caalri@hotmail.com


1. Skalak R, Fox CF. Tissue engineering: proceedings of a workshop, held at Granlibakken, Lake Tahoe, California, February 26-29, 1988. Liss; 1988, 343 pages. ISBN-10: 0845147064

2. Sterodimas A., De Faria J., Correa WE., Pitanguy I. Tissue engineering in  plastic surgery: an up-to-date review of the current literature. Ann Plast Surg. 2009, 62:97-103.

3. Al-Himdani S., Jessop Z.M., Al-Sabah A. et al. Tissue-Engineered Solutions in Plastic and Reconstructive Surgery: Principles and Practice. Frontiers in Surgery. 2017, 4(4):1-13.

4. Kratz G., Huss F. Tissue engineering--body parts from the Petri dish. Scand J Surg. 2003, 92:241-7.

5. Goessler UR., Hormann K., Riedel F. Tissue engineering with adult stem cells in reconstructive surgery (review). Int J Mol Med. 2005, 15:899-905.

6. Hillel AT., Elisseeff JH. Embryonic progenitor cells in adipose tissue engineering. Facial Plast Surg. 2010, 26:405-12.

7. Miller MJ., Patrick CW., Jr. Tissue engineering. Clinics in Plastic Surgery. 2003, 30:91-103.

8. Wong VW., Rustad KC., Longaker MT., Gurtner GC. Tissue engineering in plastic surgery: a review. Plast Reconstr Surg. 2010, 126:858-68.

9. Golas AR., Hernandez KA., Spector JA. Tissue engineering for plastic surgeons: a primer. Aesthetic Plast Surg. 2014, 38:207-21.

10. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006, 126:663-76.

11. Cetrulo C.L., Jr. Cord-blood mesenchymal stem cells and tissue engineering. Stem Cell Rev. 2006, 2:163-8.

12. Cerqueira MT., Pirraco RP., Martins AR., Santos TC., Reis RL., Marques AP. Cell sheet technology-driven re-epithelialization and neovascularization of skin wounds. Acta Biomater.2014, 10:3145-55.

13. Zarei F., Negahdari B. Recent progresses in plastic surgery using adipose-derived stem cells, biomaterials and growth factors. J Microencapsul. 2017, 34:699-706.

14. Kim JJ., Evans GR. Applications of biomaterials in plastic surgery. Clin Plast Surg. 2012, 39:359-76.

15. Cerqueira MT., Pirraco RP., Santos TC., Rodrigues DB., Frias AM., Martins AR., et al. Human adipose stem cells cell sheet constructs impact epidermal morphogenesis in full-thickness excisional wounds. Biomacromolecules. 2013, 14:3997-4008.

16. Gentile P., Scioli MG., Bielli A., Orlandi A., Cervelli V. Concise Review: The Use of Adipose-Derived Stromal Vascular Fraction Cells and Platelet Rich Plasma in Regenerative Plastic Surgery. Stem Cells. 2017, 35:117-34.

17. Gentile P., Orlandi A., Scioli MG., Di Pasquali C., Bocchini I., Cervelli V. Concise review: adipose-derived stromal vascular fraction cells and platelet-rich plasma: basic and clinical implications for tissue engineering therapies in regenerative surgery. Stem Cells Transl Med. 2012, 1:230-6.

18. Kim Y-J., Jeong J-H. Clinical application of adipose stem cells in plastic surgery. J Korean Med Sci. 2014, 29:462-7.

19. Naderi N., Combellack EJ., Griffin M., Sedaghati T., Javed M., Findlay MW. et al. The regenerative role of adipose-derived stem cells (ADSC) in plastic and reconstructive surgery. Int Wound J. 2017, 14:112-24.

20. Sung HM., Suh IS, Lee HB, Tak KS, Moon KM, Jung MS. Case Reports of Adipose-derived Stem Cell Therapy for Nasal Skin Necrosis after Filler Injection. Arch Plast Surg. 2012, 39:51-4.

21. Gentile P., Cervelli V. Adipose-Derived Stromal Vascular Fraction Cells and Platelet-Rich Plasma: Basic and Clinical Implications for Tissue Engineering Therapies in Regenerative Surgery. Methods Mol Biol. 2018, 1773:107-22.

22. Gentile P., Orlandi A., Scioli MG., Di Pasquali C., Bocchini I., Cervelli V. Concise review: adipose-derived stromal vascular fraction cells and platelet-rich plasma: basic and clinical implications for tissue engineering therapies in regenerative surgery. Stem cells translational medicine. 2012, 1:230-6.

23. Caterson EJ., Caterson SA. Regeneration in medicine: a plastic surgeons “tail” of disease, stem cells, and a possible future. Birth Defects Res C Embryo Today. 2018, 84:322-34.

24. Sheridan RL. Comprehensive treatment of burns. Curr Probl Surg. 2001, 38:657-756.

25. Markeson D., Pleat JM., Sharpe JR., Harris AL., Seifalian AM., Watt SM. Scarring, stem cells, scaffolds and skin repair. Journal of Tissue Engineering and Regenerative Medicine. 2015, 9:649-68.

26. Klar AS., Guven S., Biedermann T., Luginbuhl J., Bottcher-Haberzeth S., Meuli-Simmen C., et al. Tissue-engineered dermo-epidermal skin grafts prevascularized with adipose-derived cells. Biomaterials. 2014, 35:5065-78.

27. Cerqueira MT, da Silva LP, Santos TC, Pirraco RP., Correlo VM., Marques AP., et al. Human skin cell fractions fail to self-organize within a gellan gum/hyaluronic acid matrix but positively influence early wound healing. Tissue Eng Part A. 2014, 20:1369-78.

28. Cerqueira MT., da Silva LP., Santos TC., Pirraco RP., Correlo VM., Reis RL., et al. Gellan Gum-Hyaluronic Acid Spongy-like Hydrogels and Cells from Adipose Tissue Synergize Promoting Neoskin Vascularization. ACS Applied Materials & Interfaces. 2014, 6:19668-79.

29. da Silva LP., Santos TC., Rodrigues DB., Pirraco RP., Cerqueira MT., Reis RL., et al. Stem Cell-Containing Hyaluronic Acid-Based Spongy Hydrogels for Integrated Diabetic Wound Healing. Journal of Investigative Dermatology. 2017, 137:1541-51.

30. Silva LP., Pirraco R.P, Santos TC., Novoa-Carballal R., Cerqueira MT., Reis RL., et al. Neovascularization Induced by the Hyaluronic Acid-Based Spongy-Like Hydrogels Degradation Products. ACS Appl Mater Interfaces. 2016, 8:33464-74.

31. Minonzio G., Corazza M., Mariotta L., Gola M., Zanzi M., Gandolfi E., et al. Frozen adipose-derived mesenchymal stem cells maintain high capability to grow and differentiate. Cryobiology. 2014, 69:211-16.

32. Bashir MM., Sohail M., Bashir A., Khan FA., Jan SN., Imran M., et al. Outcome of Conventional Adipose Tissue Grafting for Contour Deformities of Face and Role of Ex Vivo Expanded Adipose Tissue-Derived Stem Cells in Treatment of Such Deformities. J Craniofac Surg. 2018, 29:1143-7.

33. Lequeux C., Rodriguez J., Boucher F., Rouyer O., Damour O., Mojallal A., et al. In vitro and in vivo biocompatibility, bioavailability and tolerance of an injectable vehicle for adipose-derived stem/stromal cells for plastic surgery indications. J Plast Reconstr Aesthet Surg. 2015, 68:1491-7.

34. Kolle SF., Fischer-Nielsen A., Mathiasen AB., Elberg JJ., Oliveri RS., Glovinski PV., et al. Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trial. Lancet. 2013, 382:1113-20.

35. Lee HC., An SG., Lee HW., Park JS., Cha KS., Hong TJ., et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J.  2012, 76:1750-60.

36. Tiryaki T., Findikli N., Tiryaki D. Staged stem cell-enriched tissue (SET) injections for soft tissue augmentation in hostile recipient areas: a preliminary report. Aesthetic Plast Surg. 2011, 35:965-71.

37. Alperovich M., Lee ZH., Friedlander PL., Rowan BG., Gimble JM., Chiu ES. Adipose stem cell therapy in cancer reconstruction: a critical review. Ann Plast Surg. 2014, 73:104-7.

38. Yoshimura K., Asano Y., Aoi N., Kurita M., Oshima Y., Sato K., et al. Progenitor-enriched adipose tissue transplantation as rescue for breast implant complications. Breast J. 2010, 16:169-75.

39. Wang L., Lu Y., Luo X., Fu MG., Hu X., Dong H., et al. „Cell-assisted lipotransfer for breast augmentation: a report of 18 patients“. Zhonghua zheng xing wai ke za zhi= Zhonghua zhengxing waike zazhi= Chinese journal of plastic surgery, 2012, 28.1:1-6.

40. Yoshimura K., Sato K., Aoi N., Kurita M., Hirohi T., Harii K. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg. 2008, 32:48-55.

41. Zimmerlin L., Donnenberg AD., Rubin JP., Basse P., Landreneau RJ., Donnenberg VS. Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Eng Part A. 2011, 17:93-106.

42. Altman AM., Prantl L., Muehlberg FL., Song YH., Seidensticker M., Butler CE., et al. Wound microenvironment sequesters adipose-derived stem cells in a murine model of reconstructive surgery in the setting of concurrent distant malignancy. Plast Reconstr Surg. 2011, 127:1467-77.

43. Sun B., Roh KH., Park JR., Lee SR., Park SB., Jung JW., et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy. 2009, 11:289-98.

44. Alvarez PD., Garcia-Arranz M.., Georgiev-Hristov T, Garcia-Olmo D. A new bronchoscopic treatment of tracheomediastinal fistula using autologous adipose-derived stem cells. Thorax. 2008, 63:374-6.

45. Lott DG., Janus JR.. Tissue engineering for otorhinolaryngology-head and neck surgery. Mayo Clin Proc. 2014, 89:1722-33.

46. Nyberg EL., Farris AL., Hung BP., Dias M., Garcia JR., Dorafshar AH., et al. 3D-Printing Technologies for Craniofacial Rehabilitation, Reconstruction, and Regeneration. Ann Biomed Eng. 2017, 45:45-57.

47. Wiggenhauser PS., Schantz JT., Rotter N. Cartilage engineering in reconstructive surgery: auricular, nasal and tracheal engineering from a surgical perspective. Regen Med. 2017, 12:303-14.

48. Man D., Plosker H., Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg. 2001, 107:229-37.

49. Powell DM., Chang E., Farrior EH. Recovery from deep-plane rhytidectomy following unilateral wound treatment with autologous platelet gel: a pilot study. Arch Facial Plast Surg. 2001, 3:245-50.

50. Guerrerosantos J., Guerrerosantos F., Orozco J. Classification and treatment of facial tissue atrophy in Parry-Romberg disease. Aesthetic Plast Surg. 2007, 31:424-34.

51. Guerrerosantos J. Evolution of Technique: Face and Neck Lifting and Fat Injections. Clinics in Plastic Surgery. 2008, 35:663-76.

52. Cervelli V., Gentile P. Use of cell fat mixed with platelet gel in progressive hemifacial atrophy. Aesthetic Plast Surg. 2009, 33:22-7.

53. Coleman SR. Long-term survival of fat transplants: controlled demonstrations. Aesthetic Plast Surg. 1995, 19:421-5.

54. Grimaldi M , Gentile P , Labardi L , Silvi E , Trimarco A , Cervelli V. Lipostructure technique in Romberg syndrome. J Craniofac Surg. 2008, 19:1089-91.

55. Hixon KR., Melvin AM., Lin AY., Hall AF., Sell SA. Cryogel scaffolds from patient-specific 3D-printed molds for personalized tissue-engineered bone regeneration in pediatric cleft-craniofacial defects. J Biomater Appl. 2017, 32:598-611.

56. Azami M., Samadikuchaksaraei A., Poursamar SA. Synthesis and characterization of a laminated hydroxyapatite/gelatin nanocomposite scaffold with controlled pore structure for bone tissue engineering. Int J Artif Organs. 2010, 33:86-95.

57. Thesleff T., Lehtimaki K., Niskakangas T., Mannerstrom B., Miettinen S., Suuronen R., et al. Cranioplasty with adipose-derived stem cells and biomaterial: a novel method for cranial reconstruction. Neurosurgery. 2011, 68:1535-40.

58. Lendeckel S., Jodicke A., Christophis P., Heidinger K., Wolff J., Fraser JK., et al. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. J Craniomaxillofac Surg. 2004, 32:370-3.

59. Sandor GK., Numminen J., Wolff J., Thesleff T., Miettinen A., Tuovinen VJ., et al. Adipose stem cells used to reconstruct 13 cases with cranio-maxillofacial hard-tissue defects. Stem Cells Transl Med. 2014, 3:530-40.

60. Petite H., Viateau V., Bensaid W., Meunier A., de Pollak C., Bourguignon M., et al. Tissue-engineered bone regeneration. Nat Biotechnol. 2000, 18:959-63.

61. Warnke PH., Springer IN., Wiltfang J., Acil Y., Eufinger H., Wehmoller M., et al. Growth and transplantation of a custom vascularised bone graft in a man. Lancet. 2004, 364:766-70.

62. Chin M., Ng T., Tom WK., Carstens M. Repair of alveolar clefts with recombinant human bone morphogenetic protein (rhBMP-2) in patients with clefts. J Craniofac Surg. 2005, 16:778-89.

63. Yanaga H., Imai K., Yanaga K. Generative surgery of cultured autologous auricular chondrocytes for nasal augmentation. Aesthetic Plast Surg. 2009, 33:795-802.

64. Fulco I., Miot S., Haug MD., Barbero A., Wixmerten A., Feliciano S., et al. Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial. Lancet. 2014, 384:337-46.

65. Storck K., Staudenmaier R., Buchberger M., Strenger T., Kreutzer K., von Bomhard A., et al. Total reconstruction of the auricle: our experiences on indications and recent techniques. Biomed Res Int. 2014;2014: ID 373286.1-15. Doi: 10.1155/2014/373286.

66. Yanaga H., Imai K., Fujimoto T., Yanaga K. Generating ears from cultured autologous auricular chondrocytes by using two-stage implantation in treatment of microtia. Plast Reconstr Surg. 2009, 124:817-25.

67. Propst EJ., Prager JD., Meinzen-Derr J., Clark SL., Cotton RT., Rutter MJ. Pediatric tracheal reconstruction using cadaveric homograft. Arch Otolaryngol Head Neck Surg. 2011, 137:583-90.

68. Rich JT., Gullane PJ. Current concepts in tracheal reconstruction. Curr Opin Otolaryngol Head Neck Surg. 2012, 20:246-53.

69. Yu P, Clayman GL, Walsh GL. Long-term outcomes of microsurgical reconstruction for large tracheal defects. Cancer. 2011, 117:802-8.

70. Hamilton NJ., Kanani M., Roebuck DJ., Hewitt RJ., Cetto R., Culme-Seymour EJ., et al. Tissue-Engineered Tracheal Replacement in a Child: A 4-Year Follow-Up Study. Am J Transplant. 2015, 15:2750-7.

71. Delaere P., Vranckx J., Verleden G., De Leyn .P, Van Raemdonck D. Tracheal allotransplantation after withdrawal of immunosuppressive therapy. N Engl J Med. 2010, 362:138-45.

72. Neovius E., Engstrand T. Craniofacial reconstruction with bone and biomaterials: review over the last 11 years. J Plast Reconstr Aesthet Surg. 2010, 63:1615-23.

73. Oppenheimer AJ,, Mesa J,, Buchman SR. Current and emerging basic science concepts in bone biology: implications in craniofacial surgery. J Craniofac Surg. 2012, 23:30-6.

74. Quarto R., Mastrogiacomo M., Cancedda R., Kutepov SM., Mukhachev V., Lavroukov A., et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 344, 2001, p. 385-386.

75. Lissenberg-Thunnissen SN., de Gorter DJ., Sier CF., Schipper IB. Use and efficacy of bone morphogenetic proteins in fracture healing. Int Orthop. 35, 2011, p. 1271-1280.

76. Nejadnik H., Hui JH., Feng Choong EP., Tai BC., Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010, 38:1110-6.

77. Wakitani S., Imoto K., Yamamoto T., Saito M., Murata N., Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002, 10:199-206.

78. Orozco L., Munar A., Soler R., Alberca M., Soler F., Huguet M., et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013, 95:1535-41.

79. Brittberg M., Lindahl A., Nilsson A., Ohlsson C., Isaksson O., Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994, 331:889-95.

80. James R., Kumbar SG., Laurencin CT., Balian G., Chhabra AB. Tendon tissue engineering: adipose-derived stem cell and GDF-5 mediated regeneration using electrospun matrix systems. Biomed Mater. 2011, 6.2:025011. Doi: 10.1088/1748-6041/6/2/025011

81. Kwee BJ., Mooney DJ. Biomaterials for skeletal muscle tissue engineering. Curr Opin Biotechnol. 2017, 47:16-22.

82. Li GN., Hoffman-Kim D. Tissue-engineered platforms of axon guidance. Tissue Eng Part B Rev. 2008, 14:33-51.

83. Sowa Y., Imura T., Numajiri T., Nishino K., Fushiki S. Adipose-derived stem cells produce factors enhancing peripheral nerve regeneration: influence of age and anatomic site of origin. Stem Cells Dev. 2012, 21:1852-62.

84. Terenghi G., Wiberg M., Kingham PJ. Chapter 21: Use of stem cells for improving nerve regeneration. Int Rev Neurobiol. 2009, 87:393-403.

85. Shin’oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. N Engl J Med. 2001, 344(7):532-3.

86. L’Heureux N., Paquet S., Labbe R., Germain L., Auger FA. A completely biological tissue-engineered human blood vessel. Faseb j. 1998, 12:47-56.

87. Peck M., Gebhart D., Dusserre N., McAllister TN., L’Heureux N. The evolution of vascular tissue engineering and current state of the art. Cells Tissues Organs. 2012, 195:144-58.

88. Niklason LE., Gao J., Abbott WM., Hirschi KK., Houser S., Marini R., et al. Functional arteries grown in vitro. Science. 1999, 284:489-93.

89. Xu ZC., Zhang Q., Li H. Human hair follicle stem cell differentiation into contractile smooth muscle cells is induced by transforming growth factor-beta1 and platelet-derived growth factor BB. Mol Med Rep. 2013, 8:1715-21.

90. Costa M., Cerqueira MT., Santos TC.., Sampaio-Marques B, Ludovico P., Marques AP., et al. Cell sheet engineering using the stromal vascular fraction of adipose tissue as a vascularization strategy. Acta Biomater. 2017, 55:131-43.

91. Costa M., Pirraco RP., Cerqueira MT., Reis RL., Marques AP. Growth Factor-Free Pre-vascularization of Cell Sheets for Tissue Engineering. Methods Mol Biol. 2016, 1516:219-26.

Plastic surgery Orthopaedics Burns medicine Traumatology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account